Trials / Unknown
UnknownNCT05462587
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4 (estimated)
- Sponsor
- AUG Therapeutics · Industry
- Sex
- All
- Age
- 6 Months – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVTX-803 (L-Fucose) | L-fucose crystalline powder |
Timeline
- Start date
- 2022-07-28
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
- First posted
- 2022-07-18
- Last updated
- 2024-11-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05462587. Inclusion in this directory is not an endorsement.